Sid P Kerkar1, Clinton D Kemp, Itzhak Avital. 1. Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: The 5-year survival of patients receiving standard-of-care chemotherapy for metastatic gastric cancer (MGC) to the liver is <2%. This review examines the published data on liver resections for MGC and analyses the rationale for potentially aggressive surgical management. METHODS: A search of the PubMed and Scopus databases was used to identify studies published in English from 1990 to 2009 that reported on 10 or more patients who underwent liver resections for MGC. All available clinicopathologic data were analysed. In particular, we examined longterm survival and the characteristics of individuals surviving for >5 years. RESULTS: Nineteen studies reported on 436 patients. Median 5-year survival was 26.5% (range: 0-60%). Overall, 13.4% (48/358) of patients were alive at 5 years and studies with extended follow-up reported that 4.0% (7/174) of patients survived for >10 years. Overall in-hospital mortality was 3.5% (12/340 patients); however, the median mortality rate across the studies was 0%. No prognostic factor was found to be consistently statistically significant across these small studies. CONCLUSIONS: Despite the limitations of any analysis of retrospective data for highly selected groups of patients, it would appear that liver resections combined with systemic therapy for MGC can result in prolonged survival.
BACKGROUND: The 5-year survival of patients receiving standard-of-care chemotherapy for metastatic gastric cancer (MGC) to the liver is <2%. This review examines the published data on liver resections for MGC and analyses the rationale for potentially aggressive surgical management. METHODS: A search of the PubMed and Scopus databases was used to identify studies published in English from 1990 to 2009 that reported on 10 or more patients who underwent liver resections for MGC. All available clinicopathologic data were analysed. In particular, we examined longterm survival and the characteristics of individuals surviving for >5 years. RESULTS: Nineteen studies reported on 436 patients. Median 5-year survival was 26.5% (range: 0-60%). Overall, 13.4% (48/358) of patients were alive at 5 years and studies with extended follow-up reported that 4.0% (7/174) of patients survived for >10 years. Overall in-hospital mortality was 3.5% (12/340 patients); however, the median mortality rate across the studies was 0%. No prognostic factor was found to be consistently statistically significant across these small studies. CONCLUSIONS: Despite the limitations of any analysis of retrospective data for highly selected groups of patients, it would appear that liver resections combined with systemic therapy for MGC can result in prolonged survival.
Authors: J Lee; W K Kang; J M Kwon; S Y Oh; H R Lee; H J Kim; B B Park; H Y Lim; M J Han; J O Park; Y S Park Journal: Ann Oncol Date: 2006-09-13 Impact factor: 32.976
Authors: René Adam; Laurence Chiche; Thomas Aloia; Dominique Elias; Rémy Salmon; Michel Rivoire; Daniel Jaeck; Jean Saric; Yves Patrice Le Treut; Jacques Belghiti; Georges Mantion; Gilles Mentha Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: M Miyazaki; H Itoh; K Nakagawa; S Ambiru; H Shimizu; A Togawa; M Shiobara; M Ohtsuka; K Sasada; Y Shimizu; S Yoshioka; N Nakajima; T Suwa; F Kimura Journal: Am J Gastroenterol Date: 1997-03 Impact factor: 10.864
Authors: D Elias; A Cavalcanti de Albuquerque; P Eggenspieler; B Plaud; M Ducreux; M Spielmann; C Theodore; S Bonvalot; P Lasser Journal: J Am Coll Surg Date: 1998-11 Impact factor: 6.113